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Exposure to inorganic arsenic increases the risk of
basal cell carcinoma (BCC). Arsenic metabolism is a
susceptibility factor for arsenic toxicity, and specific
haplotypes in arsenic (13 oxidation state) methyl-
transferase (AS3MT) have been associated with
increased urinary fractions of the most toxic arsenic
metabolite, methylarsonic acid (MMA). The aim of
this study is to elucidate the association of AS3MT
haplotypes with arsenic metabolism and the risk of
BCC. FourAS3MT polymorphismswere genotyped in
BCC cases (N5529) and controls (N5533) from
Eastern Europewith low tomoderate arsenic exposure
(lifetime average drinking water concentration: 1.3
mg/L, range 0.01–167 mg/L). Urinary metabolites
[inorganic arsenic (iAs), MMA, dimethylarsinic acid
(DMA)] were analyzed by HPLC-ICPMS. Five AS3MT
haplotypes (based on rs3740400 A/C, rs3740393
G/C, rs11191439 T/C and rs1046778 T/C) had
frequencies >5%. Individuals with the CCTC haplo-
type had lower %iAs (P50.032) and %MMA
(P50.020) in urine, and higher %DMA (P50.033);
individuals with the CGCT haplotype had higher
%MMA (P<0.001) and lower %DMA (P<0.001).
All haplotypes showed increased risk of BCC with
increasing arsenic exposure through drinking water
(ORs 1.1–1.4, P values from <0.001 to 0.082),
except for the CCTC haplotype (OR 1.0, CI 0.9–1.2,
P value 0.85). The results suggest that carriage of
AS3MT haplotypes associated with less-efficient
arsenic methylation, or lack of AS3MT haplotypes
associated with a more-efficient arsenic methylation,
results in higher risk of arsenic-related BCC. The fact
that AS3MT haplotype status modified arsenic metab-
olism, and in turn the arsenic-related BCC risk, sup-
ports a causal relationship between low-level arsenic
exposure and BCC. Environ. Mol. Mutagen. 56:60–
69, 2015. VC 2014 The Authors. Environmental and
Molecular Mutagenesis published by Wiley Periodicals, Inc. on
behalf of Environmental Mutagen Society
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INTRODUCTION
Inorganic arsenic occurs globally in drinking water,
particularly ground water, and elevated exposure has been
associated with increased risk of nonmelanoma skin can-
cers, including basal cell carcinoma (BCC) [Hughes
et al., 2011; Karagas et al., 2001; IARC, 2012; Leonardi
et al., 2012]. Humans, however, show marked variation in
susceptibility to arsenic toxicity. The main known suscepti-
bility factors are gender, nutrition, and the efficiency of
metabolizing arsenic [Vahter, 2002]. Inorganic arsenic (iAs)
is methylated in the body to methylarsonic acid (MMA) and
dimethylarsinic acid (DMA). In humans, like most mam-
mals, efficient methylation from iAs to DMA is associated
with decreased reactivity and increased rate of urinary
arsenic excretion [Vahter, 2002; Gardner et al., 2011]. Indi-
viduals and populations, however, show major differences in
arsenic metabolism. Incomplete and less-efficient arsenic
metabolism, with higher urinary fractions of iAs and MMA
and lower fractions of DMA, seems to be a marker of sensi-
tivity to certain arsenic-related diseases, including cancer
[Lindberg et al., 2008b; Chung et al., 2009].
Genetic variants in the main arsenic-methylating
enzyme, arsenic (13 oxidation state) methyltransferase
(AS3MT), have been shown to modify arsenic metabolism
in several populations [Sumi and Himeno, 2012]. For
eight AS3MT single nucleotide polymorphisms (SNPs)
combined into haplotypes, four AS3MT haplotypes had
similar effects on the arsenic metabolite pattern in two
different populations, one from Argentina and one from
Bangladesh [Engstrom et al., 2011]. Associations between
AS3MT polymorphisms and toxic effects, such as skin
lesions, have also been reported [Valenzuela et al., 2009;
Pierce et al., 2012]. Our hypothesis is that AS3MT haplo-
types that are associated with the arsenic metabolite pat-
tern also are associated with the arsenic-related risk of
BCC.
MATERIALS ANDMETHODS
Study Population
Within a European case–control study that previously identified
arsenic exposure in drinking water to be associated with risk of BCC
[Leonardi et al., 2012] we evaluated the impact of AS3MT haplotypes
on: (1) the urinary pattern of arsenic metabolites (controls only) and (2)
the association between lifetime arsenic concentration and BCC risk
(cases and controls). BCC cases (N5 529) and controls (N5 533) were
recruited as part of a large case–control study designed to evaluate the
risk of various cancers in relation to low environmental arsenic exposure
in Hungary, Romania, and Slovakia between 2002 and 2004 [Leonardi
et al., 2012]. Study areas were defined as certain counties (total popula-
tion 2.8 million) in Hungary (Bacs, Bekes, Csongrad, and Jazs-Nagykun-
Szolnok), Romania (Bihor and Arad) and Slovakia (Banska Bystrica and
Nitra) [Lindberg et al., 2006]. These areas were selected because of
past, and in some places ongoing, arsenic exposure through drinking
water, including public water supplies. Exposure assessment was based
on measurements of water supplies in the study, and data from routine
monitoring of water in the past [Hough et al., 2010]. Overall, 25% of
the population had a lifetime average water concentration above 10 mg/L
and 8% above 50 mg/L [Hough et al., 2010]. The large majority of the
study participants were of European ancestry.
Table I shows descriptive data of the study subjects. Incident cases of
BCC (ICD-10 code C44) were identified and invited on the basis of his-
topathological examinations by pathologists. These were compared with
hospital-based controls (general surgery, orthopedic and trauma patients
with, for example, appendicitis, abdominal hernias, duodenal ulcers,
cholelithiasis, and fractures), which were selected and included in the
study based on a published set of criteria [Leonardi et al., 2012]. They
were frequency-matched with the cases for age, gender, and county of
residence. Patients with malignant tumors, diabetes or cardiovascular
diseases were excluded as study controls. Cases and controls were
included if they had resided in the study area for at least 1 year during
their lifetime. Clinicians and pathologists were blinded to the exposure
status of cases and controls.
Cases and controls were interviewed by trained personnel and they
completed a general questionnaire, which included information on
detailed residential history focused on identification of drinking water
sources at home, individual cumulative sun exposure in summer, skin
complexion, effects of sun exposure on skin and age(s) at diagnosis of
BCC. Skin sensitivity to burns (effects of sun exposure) is an index
based on the reported intensity of the cutaneous reaction to 1 hr midday
sun exposure of the upper trunk, and skin complexion as the self-
reported complexion of the skin as light, medium or dark. Clinicians
collected venous blood and urine samples from cases and controls after
the study participants had signed consent forms. The blood samples
were kept frozen at 280C until analysis. Further details about the
study populations and sampling have been described previously [Lind-
berg et al., 2006; Thirumaran et al., 2006; Leonardi et al., 2012; Surdu
et al., 2013].
Ethical approval was obtained from the Ethical Committee of the
National Health Research Council and the Regional Ethical Committee
of the Szent-Gyorgyi Albert University of Szeged (Hungary), from local
hospitals and Public Health Departments (Romania), and from Ethical
Committees established in hospitals and State Health Institutes
(Slovakia).
Arsenic Exposure Assessment
All water samples were analyzed by one laboratory, using hydride
generation-atomic absorption spectrometry (HG-AAS), with a limit of
detection (LOD) of 0.2 mg/L [Hough et al., 2010]. The exposure assess-
ment details are described in [Hough et al., 2010]. In short, for each
individual, the concentrations of arsenic in drinking water at addresses
over their lifetime were derived from measurements at the time of the
study and historical data provided by national water authorities. If histor-
ical data were not available, concentrations of arsenic in village, and pri-
vate wells were assumed to have been the same as the currently
measured concentrations. The lifetime average arsenic concentration (mg/
L) constitutes the time-weighted average concentration of arsenic in resi-
dential drinking water over all the years with nonmissing arsenic con-
centrations over a participant’s lifetime. This variable was used as a
measure of lifetime arsenic exposure in this study. Ten individuals (four
controls and six cases) had missing data for lifetime average arsenic
concentration and were thus excluded from the BCC analyses.
Arsenic Metabolism
Urine samples were collected for determination of individual arsenic
metabolite patterns. Only urine samples from the controls were included
in this study, as disease status may affect arsenic metabolism. Each par-
ticipant was asked to provide an early morning urine sample. The sam-
ples were frozen at 220C within 15 min of collection. Urinary
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metabolites iAs, MMA, and DMA were measured with HPLC online
with inductively coupled plasma-mass spectrometry (ICPMS) [Lindberg
et al., 2006]. Total urinary arsenic metabolites (U-As), computed as the
sum of iAs, MMA, and DMA, were used as a measure of the current
exposure to iAs. The fractions (%) of the different metabolites in urine
were used to assess the efficiency of arsenic metabolism. Concentrations
of arsenic in urine were adjusted to the average specific gravity of the
urine (1.018 g/mL) in the study population. There was a cluster of val-
ues close to 100% DMA at the lowest water arsenic concentrations,
which likely was due to contribution of DMA from certain foods [Lind-
berg et al., 2006]. Additionally, there were uncertainties in the speciation
data of urine samples with very low concentrations, as DMA is often the
only species well above the limit of detection. Because such uncertain-
ties would invalidate the urinary arsenic metabolite pattern as marker of
arsenic methylation efficiency, we decided to include only individuals
with total urinary arsenic metabolite concentrations >5 lg/L (N5 285)
in the genetic association analyses. Another eight individuals were
excluded because they had high urinary arsenic concentrations (above 20
mg/L) and low water arsenic concentrations (below 1 mg/L) in combina-
tion with a high percentage of DMA in the urine (above 80%), suggest-
ing food as a major source of DMA. The sample size after these
exclusions was 277 individuals. For %iAs and %MMA, the numbers
were somewhat lower (N5 269 and 245, respectively) since individuals
with fractions of 0% were excluded when natural log (ln) transforming
the data.
Genotyping
Several SNPs in AS3MT have been associated with arsenic metabolite
pattern [review in Sumi and Himeno, 2012]. To evaluate if genetic vari-
ation in AS3MT influences the risk of arsenic-related BCC risk, we geno-
typed four SNPs, all of which were present in haplotypes that we
previously have shown are associated with arsenic metabolism in popu-
lations from Argentina and Bangladesh [Engstr€om et al., 2011]. The
selection of SNPs to be genotyped was based on the following observa-
tions. Rs11191439 is a nonsynonymous SNP and carriers of the C-allele
(coding for Thr) have higher %iAs, higher %MMA and lower %DMA
compared to TT carriers [Drobna et al., 2004; Lindberg et al., 2007;
Hernandez et al., 2008; Engstrom et al., 2011], i.e., less efficient arsenic
metabolism. Carriers of the intronic rs3740400 A- and rs3740393
G-alleles, as well as rs1046778 (located in the 30-untranslated region)
TABLE II.AS3MT Haplotype Frequencies by Country
Haplotypea Hungary Romania Slovakia All More efficient arsenic metabolismb
Haplotype 1—AGTT 51%c 57% 52% 53% 0 copies
0/1/2 copies 25/47/28 23/42/36 21/54/25 23/48/29
Haplotype 2—CCTC 10% 12% 14% 12% 1–2 copies
0/1/2 copies 82/17/1 78/20/2 75/24/2 78/20/2
Haplotype 3—CGTC 18% 14% 16% 16% 1–2 copies
0/1/2 copies 66/31/3 75/22/3 71/26/3 70/27/3
Haplotype 4—CGCT 11% 11/% 10% 11% 0 copies
0/1/2 copies 78/21/1 79/20/1 82/17/1 80/19/1
Haplotype 5—ACTC 7% 5% 5% 6% NAd
0/1/2 copies 87/12/0.5 89/11 87/13/0.5 88/12/0.3
Haplotype 6—CGTT 2% 1% 2% 2% NA
0/1/2 copies 96/4/0 98/2/0 96/4/0 96/4/0
Haplotype 7—AGTC <1% <1% <1% <1% NA
0/1/2 copies 100/<1%/0 100/<1%/0 100/<1%/0 100/<1%/0
aThe SNPs are, in the 5’ to 3’ direction: rs3740400, rs3740393, rs11191439 and rs1046778.
bDenotes the haplotype previously associated with a more efficient arsenic methylation (lower fractions of iAs or MMA and/or higher DMA in urine)
[Engstrom et al. 2011].
cFrequency of the haplotype.
dNA5 not available.
TABLE I.Characteristics of the Study Population
Variable
Controls Cases
N Median Min Max N Median Min Max
Age (years) 533 61 28 83 529 66 30 85
BMI (kg/m2) 510 27 13 48 501 27 16 48
Lifetime water arsenic conc. (per 10 mg/L) 529 1.8 0.01 167 523 1.06 0.09 140
Gender (% women) 533 49 529 55
Smoking (% yes) 502 53 496 65
Country (N) 533 529
Hungary 242 160
Romania 156 158
Slovakia 135 211 ‘
BMI (body mass index), N5 number of individuals.
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T-alleles have higher %iAs, higher %MMA and lower %DMA compared
with reference genotypes [Meza et al., 2005; Agusa et al., 2009; Chung
et al., 2009; Engstrom et al., 2011], indicating less-efficient metabolism.
Rs3740400 and rs1046778 have been associated with gene expression of
AS3MT as well [Engstr€om et al., 2011, 2013].
DNA was isolated from peripheral blood using Qiagen mini-
preparation kits (Qiagen GmbH, Hilden, Germany). The four AS3MT
SNPs (rs11191439, rs3740400, rs3740393, and rs1046778) were geno-
typed by allelic discrimination with Taqman assays (Applied Biosystems
Foster City, CA) on an ABI 7900 instrument (Applied Biosystems).
Haplotypes were constructed on the combination of these four SNPs
using PHASE [Stephens and Donnelly, 2003]. Haplotype frequencies are
presented in Table II together with the associations between haplotype
and arsenic metabolism reported in other populations [Engstrom et al.,
2011]. Although the haplotypes in Engstrom et al. [2011] were based on
eight SNPs, the haplotype frequencies were similar when based on the
four SNPs included in the present study. The genomic region where
AS3MT is situated (10q24) has been shown to have a long linkage dise-
quilibrium (LD) block spanning over the AS3MT gene [Engstrom et al.,
2013].
Statistical Analyses
Deviation from Hardy–Weinberg equilibrium was tested using chi-
square analysis. The LD pattern was evaluated in each country by Hap-
loview [Barrett et al., 2005]. Individuals from all three study areas were
pooled in the statistical analyses. Groups with one or two haplotype cop-
ies were pooled, since there were few individuals with two haplotype
copies in all groups, with exception for haplotype 1.
Associations between haplotypes (independent variable) and urinary
arsenic metabolites were evaluated by multivariable-adjusted regression
analyses with %iAs, %MMA, and %DMA as dependent variables. These
variables were used as continuous variables, and in order to achieve nor-
mally distributed residuals, %iAs and %MMA were natural log (ln)
transformed in all analyses. For covariate inclusion, univariate models
were performed, evaluating the association of the biologically relevant
variables with each metabolite (dependent variables). Variables with
P< 0.10 were included in the final multivariable-adjusted regression
model together with haplotype (as categorical variable). The following
variables were tested: U-As (mg/L, continuous variable), age, gender,
cigarette smoking (yes/no), county, and BMI. The final models for
AS3MT and metabolites are presented in Table III. Arsenic exposure
(measured as U-As) has been shown to influence the arsenic metabolite
pattern in high-exposed individuals in Bangladesh and Argentina
[Engstr€om et al., 2011]. We therefore evaluated the influence of U-As
on the arsenic metabolite pattern in this population. However, including
U-As into the models did not impact on the associations between haplo-
type and metabolite pattern (data not shown) and we did not adjust for
arsenic exposure in the final models.
We stratified the study population according to haplotype and used
unconditional logistic regression to evaluate the association between
average lifetime water arsenic concentration (per 10 mg/L increase, con-
tinuous variable) and BCC risk. A separate model, not stratified for hap-
lotype, provided the P value for the interaction term (haplotype 3
lifetime arsenic concentration). Case/control status was used as the
dependent variable in all analyses.
The following covariates were included in the logistic regression
models: age, gender, years of education (three groups, defined as “below
8 years”, between 8 and 12 years” and “above 12 years”), county (since
the number of controls per case varied by county [Leonardi et al.,
2012], as well as the two indices of sun exposure that most strongly pre-
dicted BCC risk: skin complexion (three groups, defined as “light”,
“medium”, and “dark”) and skin response to 1 hr of midday sun (five
groups, defined as “blistered”, “sunburnt”, “mild burn”, “tan”, and “no
change”). As neither smoking, nor body mass index (BMI), are likely
confounders for BCC, and these covariates did not alter the magnitude
of associations (data not shown), we did not include them in the final
models.
We also evaluated combinations of two haplotypes, giving four com-
bined groups (for example, the combinations of haplotypes 1 and 2 gave
the following groups: (a) zero copies of haplotype 1 and zero copies of
haplotype 2; (b) one or two copies of haplotype 1 and zero copies of
haplotype 2; (c) zero copies of haplotype 1 and one or two copies of
haplotype 2; and (d) one or two copies of haplotype 1 and one or two
copies of haplotype 2). We combined haplotypes based on the results
from the analyses encompassing a single haplotype. In the analysis of
metabolite pattern, we combined haplotypes that were significantly asso-
ciated with arsenic metabolites. For the analysis of BCC risk, we com-
bined haplotypes that were either significantly associated with
metabolites or haplotypes that showed a significant effect modification
with BCC risk (based on the hypothesis that bcc risk could be influenced
by both metabolite pattern or directly by the haplotype). Haplotypes
TABLE III.Geometric Mean Metabolite Fractions (Arithmetic
Mean for %DMA) for each AS3MT Haplotype and P values
from Multivariate Regression Analyses (Controls Only)a
Haplotype/haplotype
combinations
Controls with total urinary arsenic >5 mg/L
%iAs (N) %MMA (N) %DMA (N)
Haplotype 1
0 copies 8.2 (75) 15.3 (68) 72.2 (78)
1/2 copies 8.6 (194) 16.1 (177) 72.4 (199)
P valueb 0.21 0.49 0.88
Haplotype 2
0 copies 8.9 (210) 16.6 (189) 71.3 (215)
1/2 copies 6.9 (59) 13.5 (56) 76.0 (62)
P value 0.032 0.020 0.033
Haplotype 3
0 copies 8.1 (173) 15.9 (160) 73.1 (180)
1/2 copies 9.2 (96) 15.7 (85) 70.9 (97)
P value 0.24 0.92 0.25
Haplotype 4
0 copies 8.2 (210) 14.8 (192) 73.9 (216)
1/2 copies 9.5 (59) 20.5 (53) 66.9 (61)
P value 0.14 <0.001 <0.001
Haplotype 5
0 copies 8.6(234) 16.0(215) 72(240)
1/2 copies 7.8(35) 14.9(30) 74.5(37)
P value 0.26 0.30 0.11
Haplotypes 2 and 4c
1/2 and 0 copies 6.6 (48) 12.5 (45) 77.3 (50)
0 and 0 copies 8.7 (162) 15.5 (147) 72.8 (166)
1/2 and 1/2 copies 8.7 (11) 18.4 (11) 70.7 (12)
0 and 1/2 copies 9.7 (48) 21.1 (42) 66.0 (49)
P value 0.032 <0.001 <0.001
aThe multivariate models was as follows: %iAs (natural log (ln) trans-
formed)5 b1 3 haplotype1b2 3 gender1b3 3 smoking1b4 3
county1b5 3 BMI;
%MMA (ln)5 b1 3 haplotype1 b2 3 gender1 b3 3 smoking1 b4 3
BMI;
%DMA5b1 3 haplotype1 b2 3 gender1 b3 3 smoking1 b4 3
county1b5 3 BMI;
bP values presented are for haplotype term as a whole in the multivariate
regression (b1 3 haplotype).
cNumber of copies of haplotype 2 are denoted first. The groups are in
order of expected effect (the groups with the lowest expected %MMA
are first), based on the analysis of the haplotypes separately.
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were combined regardless of direction (e.g., efficient or nonefficient
methylator).
RESULTS
Genetic Background
All SNPs were in Hardy–Weinberg equilibrium. The
LD values (R2) were similar in all countries (Fig. 1) and
to those of the Hapmap European reference population
(CEPH, derived from US residents with northern and
western European ancestry (CEU) [Thorisson et al.,
2005]). Rs1046778 was in moderate LD with both
rs3740400 and rs3740393 (R25 between 0.36 and 0.46,
the C-alleles of both SNPs were associated to each
other), whereas rs11191439 was not in LD with any
SNP.
Fig.1. LD values (R2) for the AS3MT SNPs in the different study populations as well as the reference CEU population
from Hapmapa. aSNPs are shown in the 50 to 30 direction. CEU denotes the reference Hapmap population (CEPH,
derived from US residents with northern and western European ancestry, http://www.hapmap.org, no data available for
rs3740400) [Thorisson et al., 2005].
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Seven haplotypes were found in this population, five of
which had frequencies of >5% and were included in the
subsequent statistical analyses (Table II). The AGTT
(denoted haplotype 1) was the most common (SNPs are
in 50–30 order based on their position on the gene:
rs3740400, rs3740393, rs11191439, and rs1046778).
AS3MT Haplotypes and theMetabolism of Arsenic
The control individuals included in the assessment of
associations between AS3MT haplotype and arsenic
metabolizing phenotype had a geometric mean U-As con-
centration of 15.0 mg/L (N5 277, range 5.0–140 mg/L),
and geometric mean fraction of iAs of 8.5% (N5 269,
range 1.1–88%), MMA of 15% (N5 245, range 1.5–63%)
and DMA of 72% (arithmetic mean) (range 9.8–100%).
Two haplotypes, 2 and 4, were significantly associated
with the arsenic metabolite pattern (Table III). Individuals
with one or two copies of haplotype 2 had lower %iAs
(P5 0.032), lower %MMA (P5 0.020) and higher
%DMA (P5 0.033). Individuals with one or two copies
of haplotype 4 had particularly high %MMA (P< 0.001)
and low %DMA (<0.001). No statistically significant
effects were seen for the most frequently occurring haplo-
type 1.
When combining the haplotypes that influenced arsenic
metabolite pattern (haplotypes 2 and 4) (Table III) we
found that individuals with one or two copies of haplo-
type 2 and zero copies of haplotype 4 had the lowest
%iAs (P5 0.032) and %MMA (P< 0.001), and the high-
est %DMA (P< 0.001). Conversely, individuals with zero
copies of haplotype 2 and one or two copies of haplotype
4 had the highest %iAs and %MMA, and the lowest
%DMA. Individuals with zero copies of both haplotypes
2 and 4 had somewhat lower %MMA and higher %DMA
than individuals with one or two copies of both haplo-
types 2 and 4. However, the group with one or two copies
of both haplotypes 2 and 4 comprised only 11 or 12 indi-
viduals so the results for this group have low power.
AS3MT Haplotypes and Arsenic-Related BCC Risk
Based on cases and controls, the risk of BCC increased
with increasing lifetime concentration of arsenic in drink-
ing water (OR 1.2 per 10 mg/L increase, 95% CI 1.1–
1.3), as previously presented [Leonardi et al., 2012].
Results of the logistic regression analysis of haplotype-
specific associations between lifetime water arsenic con-
centrations and BCC are shown in Table IV. All haplo-
types showed increased risk of BCC with increasing
arsenic exposure. The OR:s were above 1.0 for all analy-
ses, but some analyses were not statistically significant.
ORs ranged from 1.1 to 1.4, P values ranged from
<0.001 to 0.082, except for among individuals with one
or two copies of haplotype 2 (OR 1.0, CI 0.9–1.2, P
value 0.85).
Individuals with zero copies of haplotype 1 had a
higher BCC risk with increasing lifetime concentration of
arsenic, compared to those with those with one or two
copies [zero copies: OR 1.4, CI 1.1–1.8, P value 0.001;
one copy: OR 1.2, CI 0.9–1.2, P value 0.36 (N5 492);
and two copies OR 1.2, CI 1.0–1.4 (N5 290), P value
0.054]. There was a significant effect modification
(P5 0.036). Similarly, individuals with zero copies of
haplotype 2 had a significantly increased BCC risk (OR
1.2, CI 1.1–1.4, P value <0.001; P value for interaction
0.098). Haplotypes 3, 4, and 5 all showed higher risk
with one or two copies than with zero copies.
AS3MT Haplotype Combinations and Arsenic-Related BCC
Risk
We found a significant effect modification on BCC risk
for the combination of haplotypes 1 and 2 (P5 0.010)
and haplotypes 1 and 4 (P5 0.020; Table IV). The high-
est risk among all the haplotype combinations was seen
for individuals with zero copies of both haplotype 1 and
2, who had 2.7 times higher risk in relation to arsenic
exposure (CI 1.5–4.8). Individuals with one or two copies
of haplotype 2 did not show any increased risk of BCC
with increasing arsenic exposure, irrespective of the num-
ber of copies of haplotype 1. Also, for the combination of
haplotype 1 and 4, individuals with zero copies of both
haplotypes had the highest BCC risk (OR 1.6, CI 1.1–
2.2). Individuals with zero copies of haplotype 1 in com-
bination with one or two copies of haplotype 4, which
was associated with very high urinary fraction of MMA
(Table III), showed almost as high risk (OR 1.5). Individ-
uals with one or two copies of both haplotypes had a
lower risk of BCC (OR of 1.1, CI 0.7–1.6, P value 0.79),
mainly due to the protective effects of haplotype 1. When
combining haplotypes 2 and 4, the interaction term was
not statistically significant and the analysis was hampered
by having too few individuals with one or two copies of
both haplotypes.
DISCUSSION
This study, carried out in a European population with
low to moderate arsenic exposure, confirms earlier find-
ings of an association between genetic variation in
AS3MT and arsenic metabolism in Asian or American
populations exposed to high levels of arsenic. The study
also showed that this gene, which encodes a key arsenic-
metabolizing enzyme, modifies the previously reported
association between arsenic exposure and BCC [Leonardi
et al., 2012]. Importantly, the observed gene–environment
interaction supports the hypothesis that the association
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between low-level arsenic exposure and BCC risk reflects
a causal relationship.
The directions of the results suggest that polymor-
phisms in AS3MT that associated with less-efficient
arsenic methylation (especially lack of copies of haplo-
types 1 and 2, particularly in combination, and one or
two copies of haplotype 4) are associated with a higher
risk of arsenic-related BCC. However, only haplotype 1
demonstrated a statistically significant effect modification,
where individuals with one or two copies of haplotype 1
had lower BCC risk with increasing exposure compared
to individuals with no copies of haplotype 1, but this hap-
lotype did not seem to affect arsenic metabolism. Thus,
AS3MT may influence the susceptibility to BCC via other
mechanisms not related to arsenic metabolism. Other
functions of AS3MT in the human body apart from
arsenic metabolism have not yet been elucidated. An
interesting finding was that individuals lacking both hap-
lotype 1 and 2 had an almost three times increase in BCC
risk per 10 mg/L increase in lifetime drinking water
arsenic. Similarly, those lacking both haplotypes 1 and 4
had a 60% increase in BCC risk for the same degree of
arsenic exposure. It should be noted that the speciation of
arsenic metabolites in urine was only performed in the
controls and we cannot be sure if the effects found are
the same in the individuals that developed cancer. This
fact stresses that prospective studies are needed to follow
individual arsenic metabolism and relate that to the devel-
opment of cancer.
The AS3MT haplotypes found in this population were
the same as those previously found in Argentina and Ban-
gladesh [Engstrom et al., 2011]. We also found three hap-
lotypes that were not found in the studies in Argentina or
Bangladesh: one haplotype with a frequency above 5%
TABLE IV.Association Between Lifetime Arsenic Concentration and Risk of Basal Cell Carcinoma, Stratified for Haplotype
(Logistic Regression)
Haplotype N
Effect estimatesa
Effect modificationbP OR 95% CI
Haplotype 1 0.036
0 copies 239 0.001 1.4 1.1 1.8
1/2 copies 782 0.045 1.1 1.0 1.2
Haplotype 2 0.098
0 copies 805 <0.001 1.2 1.1 1.4
1/2 copies 216 0.85 1.0 0.9 1.2
Haplotype 3 0.43
0 copies 719 0.072 1.1 1.0 1.2
1/2 copies 302 <0.001 1.4 1.2 1.8
Haplotype 4 0.58
0 copies 809 0.004 1.2 1.1 1.3
1/2 copies 212 0.025 1.3 1.0 1.6
Haplotype 5 0.054
0 copies 894 0.006 1.1 1.0 1.2
1/2 copies 127 0.082 1.3 1.0 1.8
Haplotypes 1 and 2 0.010
0 and 0 copies 140 0.001 2.7 1.5 4.8
0 and 1/2 copies 99 0.99 1.0 0.7 1.4
1/2 and 0 copies 665 0.040 1.1 1.0 1.3
1/2 and 1/2 copies 117 0.95 0.99 0.8 1.2
Haplotypes 1 and 4 0.020
0 and 0 copies 139 0.012 1.6 1.1 2.2
0 and 1/2 copies 100 0.014 1.5 1.1 2.0
1/2 and 0 copies 670 0.041 1.1 1.0 1.2
1/2 and 1/2 copies 112 0.79 1.1 0.7 1.6
Haplotypes 2 and 4 0.26
0 and 0 copies 618 0.003 1.2 1.1 1.3
0 and 1/2 copies 187 0.006 1.5 1.1 1.9
1/2 and 0 copies 191 0.52 1.1 0.9 1.3
1/2 and 1/2 copiesc 25
CI5 confidence interval, OR5 odds ratio, N5 number of individuals.
aModel included life time arsenic concentration (per 10 mg/L increase), skin complexion, skin response to 1-hr midday sun, age, gender, education,
and county.
bA separate model that included all individuals provided the P value for the effect modification (the interaction term haplotype 3 life time arsenic
concentration).
cToo few individuals to conduct any analyses.
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(haplotype 5), and two minor haplotypes. The haplotype
frequencies were similar in all European countries studied
here and included all four major haplotypes that have
been shown to affect arsenic metabolism [Engstrom et al.,
2011]. However, in the current study, the associations
between AS3MT haplotypes and metabolism differed
somewhat from the studied Asian and South American
populations in that haplotypes 1 and 3 did not modify
arsenic metabolism. This suggests that the SNPs analyzed
are not functional themselves, but are in LD with func-
tional variants that have a different LD pattern in these
European populations compared with the Argentinean and
Bangladeshi populations.
This study has several strengths. The study popula-
tion is fairly large and several of the variant alleles had
relatively high frequency. The LD analysis indicated a
similar genetic structure for the AS3MT gene in the
three different subpopulations and those could thus be
pooled to increase the power of the analyses. Differen-
ces in unmeasured confounders between countries were
partly addressed by including county, accounting for
regional differences in arsenic exposure and BCC risk,
as a variable in the models. All arsenic measurements
and genotyping analyses were made by the same
method and in the same laboratory, using adequate
quality control. However, the low levels of arsenic
exposure and the uncertainties in lifetime arsenic expo-
sure assessments have likely hampered the evaluation
of associations between AS3MT haplotypes and arsenic
metabolism. The urinary arsenic concentrations were
substantially lower in this study (median 6 mg/L for all
individuals) compared with previous studies in Argen-
tina and Bangladesh (medians 200 and 100 mg/L,
respectively [Engstrom et al., 2011]. At such low levels
of exposure, food may also be an important source of
arsenic exposure, and food may contain both iAs,
DMA, and arsenosugars, which are metabolized to
DMA in the body [Lindberg et al., 2006]. Also, other
urinary metabolites than DMA were often below the
limit of detection, distorting the true metabolite distri-
bution. Although we excluded individuals with arsenic
in urine below 5 mg/L in these analyses, the arsenic
metabolites in urine may, for some individuals, not rep-
resent exposure to exclusively inorganic arsenic. How-
ever, a limitation of this study is that for some of the
analyses (e.g., the combination of haplotypes 2 and 4)
there are a small number of individuals with certain
haplotype/haplotype combinations. We attempted to
find out if gender-specific effects of AS3MT could
explain gender differences in arsenic metabolism [Lind-
berg et al., 2008a]. However, this appears not to be the
case, as we observed similar directions of the associa-
tions for both men and women, and there were in gen-
eral no big differences in genetic effect modification
between the sexes (data not shown).
The association between genetic variation in AS3MT
and cancer is less studied than the association between
genetic variation in AS3MT and arsenic metabolism. A
recent genome-wide association study [Pierce et al.,
2012] confirmed our previous results of strong associa-
tions between AS3MT genotype and arsenic metabolism
[Schlawicke Engstrom et al., 2007; Engstrom et al., 2011]
and two SNPs in the chromosome 10 region near AS3MT
(rs9527 and rs11191659) were also associated with
increased risk for arsenic-related skin lesions [Pierce
et al., 2012]. We have previously found that AS3MT hap-
lotypes associated with levels of premalignant DNA dam-
age in women exposed to arsenic [Hossain et al., 2012,
Li et al., 2012]. To our knowledge, no studies have eval-
uated rs3740400 and arsenic-related cancer risk.
Rs11191439, rs1046778 and rs3740393 have recently
been evaluated in relation to arsenic-related bladder can-
cer. Individuals with one or more copies of the C allele
(coding for Thr) in rs11191439 (here in haplotype 4) had
an elevated risk of bladder cancer [Beebe-Dimmer et al.,
2012]. No significant effects were found for rs1046778
and rs3740393 [Lesseur et al., 2012], but many of the
analyses lacked statistical power. One study found that
the Thr-allele of the rs11191439 polymorphism associated
with a marginally increased risk of arsenic-related skin
lesions [Valenzuela et al., 2009], whereas no effect was
found in another study [De Chaudhuri et al., 2008] or in
the present study. There was no association between
rs3740393 and cancer risk (all types of cancer combined)
in a population from Taiwan [Chung et al., 2009]. Also,
two polymorphisms not evaluated in this study,
rs11191453 and rs7085104, did not affect the risk of skin
lesions in a Mexican population [Valenzuela et al., 2009].
Polymorphisms in genes other than AS3MT may also
influence BCC risk, such as SNPs in DNA repair genes
NBS1 and XRCC3, which showed effect modulation for
BCC [Thirumaran et al., 2006]. Other candidates include
SNPs in fibrous sheath interacting protein 1 (FSIP1) and
solute carrier family 39, member 2 (SLC39A2) that influ-
ence the risk of arsenic-related bladder cancer, as shown
in a study scanning 10,000 SNPs [Karagas et al., 2012] or
SNPs in p21 or glutathione S-transferase omega 1
(GSTO1) and GSTO2 that influence the risk of arsenic-
related urothelial carcinoma [Chung et al., 2008, 2011].
In conclusion, AS3MT haplotypes associated with the
arsenic metabolite profile, and possibly also other AS3MT
haplotypes, modified the risk of BCC among individuals
with low exposure to arsenic. These results may explain
part of the observed variation in susceptibility to arsenic-
related cancer.
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